+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07559786

Adebrelimab as Maintenance Therapy After Chemoradiotherapy for Adults with Limited-Stage Small Cell Lung Cancer Aged 18 to 75

Led by Henan Cancer Hospital · Updated on 2026-07-21

200

Participants Needed

2

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of adebrelimab as a follow-up treatment after concurrent chemoradiotherapy in patients with limited-stage small cell lung cancer who have not progressed. This phase 2 study involves adults aged 18 to 75 with untreated limited-stage small cell lung cancer, aiming to compare two radiation approaches combined with chemotherapy before administering adebrelimab maintenance therapy. Participants will receive one of two treatment regimens carboplatin and etoposide chemotherapy plus either residual field irradiation or involved-field radiotherapy to the thoracic area. Each chemotherapy cycle lasts 3 weeks, repeated for 4 cycles concurrently with radiotherapy. Patients who do not show disease progression after this initial treatment will then receive maintenance therapy with adebrelimab given intravenously every 3 weeks. During the study, participants will undergo regular assessments to monitor disease progression and treatment response, including imaging and laboratory tests. Researchers will measure progression-free survival up to 18 months and monitor side effects throughout treatment cycles. The study also tracks overall survival, disease control rate, and duration of response, with safety evaluations extending 30 days after the last dose. The total participation period may last up to several years, with ongoing follow-up to assess long-term outcomes.

CONDITIONS

Brief Title

A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy

Research Team

Q

Qingminf QM Wang, Professor

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here